Report Adverse Event or Product Quality Complaint   

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
    • Oncology Pipeline Tool
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ESC 2026

European Society of Cardiology

August 28 - 31, 2026

  1. All
  2. Baxfendy (baxdrostat)
  3. ATTR Amyloidosis
  4. Chronic Kidney Disease
  5. Heart Failure
  6. Dyslipidaemia
  7. Hypercholesterolaemia
  8. Hypertension
  9. Farxiga (dapagliflozin)
  10. COPD
  11. Lokelma (Sodium zirconium cyclosilicate)

PDF

Long-term efficacy and safety of baxdrostat in patients with uncontrolled or resistant hypertension: results from the BaxHTN phase 3 trial

HTML

Efficacy and safety of transthyretin gene silencer eplontersen in patients with transthyretin amyloid cardiomyopathy receiving stabiliser therapy in the CARDIO-TTRansform trial

HTML

Eplontersen in transthyretin amyloid cardiomyopathy: results from the randomised, double-blind, placebo-controlled CARDIO-TTRansform trial

HTML

Prevalence and prediction of transthyretin amyloidosis with cardiomyopathy in older patients with heart failure with preserved ejection fraction with or without left ventricular hypertrophy

HTML

Cardiorenal healthcare costs in patients with comorbid heart failure and chronic kidney disease in England, Japan, Sweden and the USA (The CaRe Study)

HTML

Study to evaluate the effect of balcinrenone/ dapagliflozin in patients with heart failure and impaired kidney function (BalanceD-HF): background and design

HTML

Characteristics, prevalence, and outcomes of patients at high risk of developing heart failure: a nationwide cohort study

PDF

Effect of diuretic dose on baxdrostat efficacy and safety in uncontrolled and resistant hypertension: a post-hoc analysis of the BaxHTN trial

PDF

Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia

PDF

Design and baseline data of AZURE-LDL, a Phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with, or at risk for, ASCVD

HTML

Personalised evaluation of NT-proBNP and clinical characteristics in suspected heart failure (PRECISE-HF)

HTML

Treatment escalation beyond triple therapy in patients with resistant hypertension: a population-based observational cohort study from UK healthcare records

HTML

Heart failure and uncontrolled hypertension: Recent evidence of routine care in Germany

HTML

Cardiorenal syndrome in German primary care: Real-world diagnostics and SGLT2 Inhibitor use

HTML

Primary care management of chronic heart failure in Germany: prevalence, diagnostics, and guideline-directed therapy in WATCH-HF 1.0 vs 2.0

HTML

Sex-specific differences in heart failure care in Germany: real-world evidence from claims data

HTML

Titration, discontinuation, and uptake of guideline-directed medical therapy for heart failure from 2020-2023: A two-nation observational study

HTML

Baseline characteristics of patients with HFrEF on dapagliflozin: final analysis of baseline data from the EVOLUTION-HF DEallEF study HFrEF cohort

HTML

Persistent gender differences in the management of chronic kidney disease in patients with heart failure - Follow-up of the InspeCKD study

HTML

Burden of cardiopulmonary events following diagnosis of COPD; a nationwide linked primary care, secondary care and death registry study

HTML

Baseline characteristics and antihypertensive patterns in Finnish patients with hypertension and kidney disease

HTML

Optimizing mineralocorticoid receptor antagonist therapy with sodium zirconium cyclosilicate in heart failure (OPRA-HF)

PDF

Efficacy and safety of AZD5462, an oral relaxin in participants with chronic heart failure: results of the phase 2b LUMINARA trial

PDF

Long-term efficacy and safety of baxdrostat in patients with uncontrolled or resistant hypertension: results from the BaxHTN phase 3 trial

PDF

Effect of diuretic dose on baxdrostat efficacy and safety in uncontrolled and resistant hypertension: a post-hoc analysis of the BaxHTN trial

HTML

Treatment escalation beyond triple therapy in patients with resistant hypertension: a population-based observational cohort study from UK healthcare records

HTML

Efficacy and safety of transthyretin gene silencer eplontersen in patients with transthyretin amyloid cardiomyopathy receiving stabiliser therapy in the CARDIO-TTRansform trial

HTML

Eplontersen in transthyretin amyloid cardiomyopathy: results from the randomised, double-blind, placebo-controlled CARDIO-TTRansform trial

HTML

Prevalence and prediction of transthyretin amyloidosis with cardiomyopathy in older patients with heart failure with preserved ejection fraction with or without left ventricular hypertrophy

HTML

Cardiorenal healthcare costs in patients with comorbid heart failure and chronic kidney disease in England, Japan, Sweden and the USA (The CaRe Study)

HTML

Persistent gender differences in the management of chronic kidney disease in patients with heart failure - Follow-up of the InspeCKD study

HTML

Cardiorenal healthcare costs in patients with comorbid heart failure and chronic kidney disease in England, Japan, Sweden and the USA (The CaRe Study)

HTML

Study to evaluate the effect of balcinrenone/ dapagliflozin in patients with heart failure and impaired kidney function (BalanceD-HF): background and design

HTML

Characteristics, prevalence, and outcomes of patients at high risk of developing heart failure: a nationwide cohort study

HTML

Personalised evaluation of NT-proBNP and clinical characteristics in suspected heart failure (PRECISE-HF)

HTML

Heart failure and uncontrolled hypertension: Recent evidence of routine care in Germany

PDF

Efficacy and safety of AZD5462, an oral relaxin in participants with chronic heart failure: results of the phase 2b LUMINARA trial

PDF

Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia

PDF

Design and baseline data of AZURE-LDL, a Phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with, or at risk for, ASCVD

PDF

Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia

PDF

Design and baseline data of AZURE-LDL, a Phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with, or at risk for, ASCVD

HTML

Heart failure and uncontrolled hypertension: Recent evidence of routine care in Germany

HTML

Baseline characteristics and antihypertensive patterns in Finnish patients with hypertension and kidney disease

HTML

Cardiorenal syndrome in German primary care: Real-world diagnostics and SGLT2 Inhibitor use

HTML

Primary care management of chronic heart failure in Germany: prevalence, diagnostics, and guideline-directed therapy in WATCH-HF 1.0 vs 2.0

HTML

Sex-specific differences in heart failure care in Germany: real-world evidence from claims data

HTML

Titration, discontinuation, and uptake of guideline-directed medical therapy for heart failure from 2020-2023: A two-nation observational study

HTML

Baseline characteristics of patients with HFrEF on dapagliflozin: final analysis of baseline data from the EVOLUTION-HF DEallEF study HFrEF cohort

HTML

Burden of cardiopulmonary events following diagnosis of COPD; a nationwide linked primary care, secondary care and death registry study

HTML

Optimizing mineralocorticoid receptor antagonist therapy with sodium zirconium cyclosilicate in heart failure (OPRA-HF)

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-115625
Last Updated 9/26

Contact Us

About Us

AstraZeneca-US.com

Other Countries

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States